HIV and Hepatitis C Conference Reports:

• Resistance Workshop - June 1999, San Diego

• First Lipodystrophy Conference - June 1999, San Diego

• ICAAC - September 1999, San Francisco

• 7th European Conference on Clinical Aspects and Treatment of HIV,
  October 1999, Lisbon

• AASLD - American Association for the Study of Liver Disease, Dallas, November 1999

• IDSA - November, 1999

We encourage you to read the articles on our website which contain more comprehensive treatment information. NATAP has an e-mail treatment news service.  When there is breaking treatment news, NATAP will e-mail to you a report of this information.  If you’d like to subscribe, free of charge, please send NATAP your e-mail address.

-.Table of Contents.- 

• Letter from the Publisher
  Correlating CD4 & Viral Load with risk for opportunistic infections; when and with what to begin therapy; resistance testing; new drugs (articles peppered throughout newsletter)

«.CONFERENCE REPORTS.»

• Structured Therapy Interruptions

• Nevirapine Antiviral Activity in High Viral Loads

• PMPA

• Combination therapy in pregnant HIV-infected Women and their newborns

• The potential role of resistance testing and therapeutic drug monitoring in the optimization of antiretroviral drug therapy

• Using IL-2 with low CD4s

• Switch to PI-sparing studies
  Switching from PI to NVP Regimen in HIV+ subjects under long-term successful treatment; switch to NVP due to lipodystrophy; switch from PI-based regimen to Efavirenz regimen; switching Protease Inhibitor Abacavir: Preliminary 16-week data (Lisbon)

• PI Sparing for Initial or First-line therapy
  (also see Lisbon late breaker on NVP in high viral loads)
  Atlantic Study; Efavirenz Studies; Abacavir; MKC-442; Three NRTIs as Initial Therapy: AZT+ddI+3TC; Pilot open-label study of 3TC+AZT+Abacavir+Efavirenz

«.PROTEASE INHIBITOR STUDIES.»

• 96-week Follow-up for Nelfinavir Twice Daily in Combination with d4T+3TC

• ABT-378: 48 week update in treatment naïve

• ABT-378/r36-Week Phase II Update: experience with One PI and NNRTI naïve

• 48 week data on Ritonavir+Indinavir

• Fortovase Twice A Day vs Three Times a Day

• 48-week Amprenavir Update

• Once Daily protease regimens: SQV+RTV, IDV+RTV, APV+RTV, 423+IDV, BMS-232632; Twice daily double PI salvage therapy: IDV+RTV and RTV+APV

«.ADDITIONAL REPORTS.»

• Efavirenz reduces methadone levels

• T20 & T-1249: a new class of drugs - Fusion Inhibitors

• Tipranavir: a new protease inhibitor

• Preliminary data - HAART + Immune Based Therapies (Remune, IL-2)

• Low and decreasing rate of viral rebound with prolonged viral suppression on HAART: insights into the long-term impact of resistance

• Detection of drug resistance mutations in HIV-1 patients with early viral rebound during ongoing combination therapy program

• Accuracy and reproducibility of ultra-low genotyping

• In vitro synergy of Abacavir and Mycophenolic Acid

• Lipodystrophy or Fat Redistribution

• Hepatitis C

Compassionate Access Programs

• ABT-378: 1 888 711-7193

• PMPA: 1 800 276-0231 (8am-6pm EST)

Small compassionate access program for ABT-378 for individuals with limited options. Larger traditional expanded access program expected to begin in early 2000. 888 711-7193. A small PMPA compassionate access program has started also for individuals with limited options.

All rights reserved. Noncommercial reproduction is encouraged. Extended reproduction requires the permission of NATAP.  All subscription lists are kept confidential.

«.Subscriptions.»

NATAP has a unique mission. We are committed to providing the most comprehensive, accurate and real-time up-to-date treatment information available. Therefore we do not have a set publication schedule. When there are advances in AIDS treatment we will publish them either in this newsletter, on our web site or if they are urgent in a priority fax or e-mail notice. 

A subscription to NATAP Reports will allow you to receive a copy of the newsletter as well as an entry on our e-mail list.

Please send us your e-mail address. All our publications are free for those who cannot afford to pay; however, we do appreciate a suggested donation for subscriptions. NATAP is a 501(c)-3 non-profit corporation, so donations are tax-deductible.

NATAP’s E-mail address is info@natap.org
Phone: 212-219-0106 or 1-888-26-NATAP
580 Broadway, Ste 1010 NY, NY 10012